UNICREDIT BANK/CALL/ELI LILLY & CO/1175/0.1/18.06.25 | Real-time BOERSE MUENCHEN 10:40:57 27/06/2024 BST | ||
| 4.18 EUR | 0.00% |
|
| Current month | +53.68% | ||
| 1 month | +55.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 4.18 | 0.00% |
| 26/06/24 | 4.18 | -4.13% |
| 25/06/24 | 4.36 | +5.06% |
| 24/06/24 | 4.15 | +5.60% |
| 21/06/24 | 3.93 | +6.22% |
Real-time BOERSE MUENCHEN
Last update June 27, 2024 at 10:40 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD4LBR |
| ISIN | DE000HD4LBR8 |
| Date issued | 12/04/2024 |
| Strike | 1,175 $ |
| Maturity | 18/06/2025 (357 Days) |
| Parity | 10 : 1 |
| Emission price | 2.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.41 € |
|---|---|
| Lowest since issue | 1.7 € |
| Spread | 0.41 € |
| Spread % | 9.13% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Warrants
- Warrant
